Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/01.wnl.0000227921.50128.55 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Douglas Mental Health University Institute, Centre for Studies on the Prevention of Alzheimer's Disease (StoP-AD), Montréal, QC, Canada.
Background: Amyloid-negative tau-positive PET (A-T+) participants have been reported in several studies. We assessed the prevalence and characteristics of A-T+ participants in a cohort of cognitively unimpaired individuals with a first-degree family history of Alzheimer's disease (AD) dementia.
Method: We studied 252 participants from the longitudinal PREVENT-AD cohort (mean cognitive follow-up = 3.
Public Health.
Alzheimers Dement
December 2024
Neurology Department, Hospital Quirónsalud Madrid, Madrid, Madrid, Spain.
Background: Identifying individuals with early Alzheimer's disease, i.e. mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) can facilitate the rapid initiation of pharmacological and non-pharmacological therapies with the aim of achieving better clinical outcomes.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Departamento de Estudios en Educación, CUCSH, Universidad de Guadalajara, Guadalajara, JA, Mexico.
Background: It is known that cardiometabolic diseases are related to Alzheimer´s Disease.
Method: We included 23 residents of Jalisco with at least one first-degree relative with ADAD (ADADG). We rated the participants using the Clinical Dementia Rating (CDR) as CDR = 0 (n = 20, 87%), CDR = 0.
Public Health.
Alzheimers Dement
December 2024
Turner Institute for Brain and Mental Health, Monash University, Melbourne, VIC, Australia.
Background: The BetterBrains Trial is a prospective behavior-modification blinded endpoint randomized controlled trial to delay cognitive decline in middle-aged adults (aged 40-70) with a family history of dementia. The primary outcome is absence of decline on at-least one out of four cognitive tests at 24-months. We present trial recruitment and current participant completion statistics and baseline demographic, modifiable dementia risk factor (MDRF) and cognitive characteristics of the randomized sample, blinded to intervention arm.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands.
Background: Participant recruitment for Alzheimer's disease (AD) research and clinical trials is challenging. Online registries can be used to identify and pre-screen eligible participants. Additional APOE genotyping has the potential to better identify individuals at-risk for AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!